Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target Discover the Best Stocks and Maximize Your Portfolio: ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Hosted on MSN20h
What To Expect From Myriad Genetics’s (MYGN) Q4 EarningsGenetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback